Kalaris Therapeutics
KLRS
75 hedge funds and large institutions have $600M invested in Kalaris Therapeutics in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 10 reducing their positions, and 10 closing their positions.
11,807% more call options, than puts
Call options by funds: $5.24M | Put options by funds: $44K
280% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 10
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
6% more funds holding
Funds holding: 71 → 75 (+4)
0.22% more ownership
Funds ownership: 1.56% → 1.78% (+0.22%)
30% less capital invested
Capital invested by funds: $854M → $600M (-$254M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$29.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28.4M |
| 3 |
BlackRock
New York
|
+$20.4M |
| 4 |
JP Morgan Chase
New York
|
+$17.9M |
| 5 |
Goldman Sachs
New York
|
+$9.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$14M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.99M |
| 3 |
TG
TCW Group
Los Angeles,
California
|
-$6.41M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$2.61M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.92M |
KLRS Hedge Fund Activity: Q1 2021 in Review
75 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2021, worth a combined $600M — down 30% from $854M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new KLRS positions and 10 closed out — a net gain of 4 holders — while 38 added to existing stakes and 10 trimmed.
The largest buyer was State Street, adding an estimated $29.6M. The largest seller was Redmile Group, cutting an estimated $14M.
- 75 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2021, up from 71 in Q4 2020.
- Funds reported $600M of Kalaris Therapeutics stock for Q1 2021, down 30% quarter-over-quarter.
- 14 funds opened new Kalaris Therapeutics positions in Q1 2021 and 10 closed out, a net change of +4 holders.
- The largest Kalaris Therapeutics buyer in Q1 2021 was State Street, an estimated $29.6M added.
- The largest Kalaris Therapeutics seller in Q1 2021 was Redmile Group, an estimated $14M sold.
Based on aggregated 13F filings for Q1 2021.